Literature DB >> 29064597

miR-23b-3p and miR-125b-5p downregulate apo(a) expression by targeting Ets1 in HepG2 cells.

Jun-Fa Zeng1, Zhao-Lin Zeng2, Kai Zhang1, Yue Zhao2, Ya-Mi Liu2, Jiao-Jiao Chen2, Hai Tong3, Dang-Heng Wei2, Zhi-Sheng Jiang2, Zuo Wang2.   

Abstract

High concentrations of plasma lipoprotein(a) [Lp(a)] have been inferred to be an independent risk factor for cardiovascular and cerebrovascular diseases, such as coronary artery diseases, restenosis, and stroke. Apolipoprotein(a) [apo(a)] is one of the most important components of Lp(a) and contributes greatly to the increased concentration of plasma Lp(a). As a critical positive transacting factor of apo(a) gene, Ets1 has been proven as a target gene of several miRNAs, such as miR-193b, miR-125b-5p, miR-200b, miR-1, and miR-499. In this study, a series of experiments on miRNAs and relative miRNAs inhibitor delivered HepG2 cells were conducted, and two miRNAs that downregulate the apo(a) by targeting the 3'-UTR of Ets1 were identified. Results showed that apo(a) and Ets1 were differentially expressed in SMMC7721 and HepG2 cell lines. Meanwhile, apo(a) and Ets1 were inversely correlated with several hepatic endogenous miRNAs, such as miR-125b-5p, miR-23b-3p, miR-26a-5p, and miR-423-5p, which were predicted to bind to Ets1. Results show that miR-125b-5p and miR-23b-3p mimics could inhibit the synthesis of apo(a) by directly targeting Ets1 in HepG2, thereby reducing the plasma Lp (a) concentration.
© 2017 International Federation for Cell Biology.

Entities:  

Keywords:  Lipoprotein (a); atherosclerosis; miR-125b-5p; miR-23b-3p

Mesh:

Substances:

Year:  2017        PMID: 29064597     DOI: 10.1002/cbin.10896

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  5 in total

1.  Hsa-miRNA-23a-3p promotes atherogenesis in a novel mouse model of atherosclerosis.

Authors:  Jiayan Guo; Hanbing Mei; Zhen Sheng; Qingyuan Meng; Murielle M Véniant; Hong Yin
Journal:  J Lipid Res       Date:  2020-10-02       Impact factor: 5.922

2.  Development of a Non-Coding-RNA-based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC.

Authors:  Ruomi Guo; Zhiqiang Wu; Jing Wang; Qingling Li; Shunli Shen; Weiwei Wang; Luyao Zhou; Wei Wang; Zhong Cao; Yu Guo
Journal:  Adv Sci (Weinh)       Date:  2019-03-07       Impact factor: 16.806

3.  Identification of key genes and long non-coding RNA associated ceRNA networks in hepatocellular carcinoma.

Authors:  Jun Liu; Wenli Li; Jian Zhang; Zhanzhong Ma; Xiaoyan Wu; Lirui Tang
Journal:  PeerJ       Date:  2019-11-01       Impact factor: 2.984

4.  TGF‑β1 affects the renal cancer miRNome and regulates tumor cells proliferation.

Authors:  Karolina Hanusek; Beata Rybicka; Piotr Popławski; Anna Adamiok-Ostrowska; Katarzyna Głuchowska; Agnieszka Piekiełko-Witkowska; Joanna Bogusławska
Journal:  Int J Mol Med       Date:  2022-02-18       Impact factor: 4.101

5.  Upregulation of miR‑423 improves autologous vein graft restenosis via targeting ADAMTS‑7.

Authors:  Wenjun Ren; Liwen Liang; Yongwu Li; Fei-Yu Wei; Ninghui Mu; Libin Zhang; Wei He; Yu Cao; Da Xiong; Hongrong Li
Journal:  Int J Mol Med       Date:  2019-12-05       Impact factor: 4.101

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.